CST logo

#6578 SignalSilence® p42 MAP Kinase (Erk2) siRNA II

  • SignalSilence® p42 MAP Kinase (Erk2) siRNA II Data Sheet PDF
CSTコード 包装
希望納入価格 (円)
国内在庫 i
2020年2月26日16時0分 現在
ご登録代理店情報 i
#6578S300 μL57,000

ERK2 製品一覧

p42 MAPK (Erk2) タンパク質の発現を特異的に抑制します。

Western Blotting

Western Blotting

Western blot analysis of extracts from 293 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® p42 MAP Kinase (Erk2) siRNA I #6540 (+) or SignalSilence® p42 MAP Kinase (Erk2) siRNA II (+), using p42 MAP Kinase (Erk2) Antibody #9108 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The p42 MAP Kinase (Erk2) Antibody confirms silencing of p42 MAP Kinase (Erk2) expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.


Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.

6201   SignalSilence® Control siRNA (Fluorescein Conjugate)
6560   SignalSilence® p44/42 MAPK (Erk1/2) siRNA
6568   SignalSilence® Control siRNA (Unconjugated)
9108   p42 MAP Kinase (Erk2) Antibody

SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.


SignalSilence® p42 MAP Kinase (Erk2) siRNA II

Metabolic Reprogramming in Disease